News About: Pharm. Affairs
The hot TNF inhibitor market with Humira, ‘King of Indication’
Humira has made a series of movements to expand its indications to secure the 1st place.
According to the current industry concerned, as the Abbvie’s ‘Humira(Adalimumab)’ added two more indications recently, it is no...
61 generic products of ‘Vesicare’ has been approved in this year
It is observed that domestic pharmaceutical companies have recently paid attention to bladder symptom treatments, followed by impotency drugs.
According to pharmaceutical product approvals of the Ministry of Food and...
Kolon Group entered the FDA Phase 3 clinical trial with the arthritis treatment ‘Invossa’ in the U.S.The world’s first degenerative arthritis gene treatment ‘Invossa™,’ developed by Kolon Group (President : Woong-yeol Lee), will get on a Phase 3 clinical trial for FDA in the U....
|
Will Belviq revive the obesity treatment market?
Belviq, the new obesity drug approved by the FDA surprisingly in 13 years, was adopted by Ildong Pharmaceutical and started to be sold in the domestic market. Known as ‘Reductil overcoming the cardiovascular side effe...
“Antibodies also go along the current trends,” having higher effectiveness yet less side effects
‘Antibodies,’ which have been used to cure cancers, are effective yet have followed side effects as well. Moreover, there has been no alternative for a patient who does not obtain any effect from the existing treatmen...
It will be obligated to report ‘serial numbers’ for every shipment of complete pharmaceutical products from next January
As scheduled, the government decided to force pharmaceutical companies to make supply reports including serial numbers for shipment of complete pharmaceutical products in January next year.
The plan is to be capable ...
Restasis, expiring in its patent on the 17th, has shaken up the xerophthalmia market
Restasis(cyclosporine, Allergan Korea), which is well known as the first xerophthalmia treatment in the world, has shaken up the market as it will be expired in its patent on the 17th of this month.
Domestic companie...
Will the notice of the Relvar Ellipta benefit reorganize asthma inhalants to once a day?
As the asthma treatment to inhale only once a day is expected to be available next month, the industry has carefully paid attention on potential competition for the treatment.
On the last December, the Ministry of He...
The ADA and the IDF set 7% for the glycemic goal for the use of HbA1c while Korea sets 6.5%
The American Diabetes Association (ADA) recommends a glycemic goal to around 7% for the use of HbA1c, and International Diabetes Federation (IDF) has also raised the goal from 6.5% to 7%.
However, the Korean Diabetes...
The 2 strong and the 1 medium has been formed by Bayer, Dong-A Pharmaceutical and Pfizer in the oral contraceptive market
As Dong-A Pharmaceutical took over the Bayer’s 4 oral contraceptives, the domestic oral
contraceptive market has become an arena for a domestic company, Dong-A Pharmaceutical, and two multinational companies, Bayer an...
